Acebrophylline: an airway mucoregulator and anti-inflammatory agent

Submitted: February 3, 2016
Accepted: February 3, 2016
Published: February 3, 2016
Abstract Views: 6705
PDF: 1888
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Acebrophylline is an airway mucus regulator with antiinflammatory action. The drug’s approach involves several points of attack in obstructive airway disease. The molecule contains ambroxol, which facilitates various steps in the biosynthesis of pulmonary surfactant, theophylline-7 acetic acid whose carrier function raises blood levels of ambroxol, thus rapidly and intensely stimulating surfactant production. The resulting reduction in the viscosity and adhesivity of the mucus greatly improves ciliary clearance. By deviating phosphatidylcholine towards surfactant synthesis, making it no longer available for the synthesis of inflammatory mediators such as the leukotrienes, acebrophylline also exerts an inflammatory effect. This is confirmed in vivo by the reduction in aspecific bronchial hyperresponsiveness in patients with stable bronchial asthma. On a clinical level, acebrophylline is therapeutically effective in patients with acute or chronic bronchitis, chronic obstructive or asthma-like bronchitis and recurrence of chronic bronchitis; it reduces the frequency of episodes of bronchial obstruction and reduces the need for β2-agonists, and improves indexes of ventilatory function.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

How to Cite

Pozzi, E. 2016. “Acebrophylline: An Airway Mucoregulator and Anti-Inflammatory Agent”. Monaldi Archives for Chest Disease 67 (2). https://doi.org/10.4081/monaldi.2007.498.